open access
The clinical significance of serum oxidative stress biomarkers in breast cancer females
Affiliations- Medical Research institute, Alexandria University, 165, El-Horrya Avenue, El-hadara, Alexandria , Egypt, 21561 Alexandria, Egypt
open access
Abstract
Background: This study was conducted to evaluate the role of some serum oxidative stress biomarkers for breast cancer diagnosis, incidence and monitoring the effects of surgery and chemotherapy. Methods: A total of 35 breast cancer patients (before surgery, after two weeks of surgery and after 6 cycles of chemotherapy) and 35 normal healthy controls were analyzed for serum oxidative stress markers including total antioxidant capacity (TAC), malondialdehyde (MDA), total, reduced (GSH) and oxidized (GSSG) glutathione and glutathione redox status (GSH/GSSG). Results: The serum levels of MDA and GSSG were significantly higher in breast cancer patients than controls. The serum levels of GSH, TAC and GSH/GSSG ratio were significantly lower in breast cancer patients than controls. After surgery, the serum levels of MDA and GSSG were significantly decreased, while the serum levels of GSH were significantly increased, compared with their levels before surgery. Six cycles of chemotherapy showed the non-significant effect on the serum levels of the assayed biomarkers. ROC curve analysis demonstrated that MDA and GSH were superior to the GSH/GSSG ratio, TAC and GSSG. Increased levels of MDA and GSSG and reduced levels of GSH, TAC and GSH/GSSG ratio were found to significantly increase the risk of breast cancer. Conclusions: All of the assayed biomarkers can be used for prediction of breast cancer with MDA and GSH being superior to the others. MDA, GSH and GSSG were able to monitor the effect of surgery. All of the assayed biomarkers were found to be associated with breast cancer risk. None of the assayed biomarkers was able to predict the effect of chemotherapy.
Abstract
Background: This study was conducted to evaluate the role of some serum oxidative stress biomarkers for breast cancer diagnosis, incidence and monitoring the effects of surgery and chemotherapy. Methods: A total of 35 breast cancer patients (before surgery, after two weeks of surgery and after 6 cycles of chemotherapy) and 35 normal healthy controls were analyzed for serum oxidative stress markers including total antioxidant capacity (TAC), malondialdehyde (MDA), total, reduced (GSH) and oxidized (GSSG) glutathione and glutathione redox status (GSH/GSSG). Results: The serum levels of MDA and GSSG were significantly higher in breast cancer patients than controls. The serum levels of GSH, TAC and GSH/GSSG ratio were significantly lower in breast cancer patients than controls. After surgery, the serum levels of MDA and GSSG were significantly decreased, while the serum levels of GSH were significantly increased, compared with their levels before surgery. Six cycles of chemotherapy showed the non-significant effect on the serum levels of the assayed biomarkers. ROC curve analysis demonstrated that MDA and GSH were superior to the GSH/GSSG ratio, TAC and GSSG. Increased levels of MDA and GSSG and reduced levels of GSH, TAC and GSH/GSSG ratio were found to significantly increase the risk of breast cancer. Conclusions: All of the assayed biomarkers can be used for prediction of breast cancer with MDA and GSH being superior to the others. MDA, GSH and GSSG were able to monitor the effect of surgery. All of the assayed biomarkers were found to be associated with breast cancer risk. None of the assayed biomarkers was able to predict the effect of chemotherapy.
Keywords
Breast cancer, MDA, TAC, GSH, GSSG, Glutathione redox status
About this articleTitle
The clinical significance of serum oxidative stress biomarkers in breast cancer females
Journal
Issue
Article type
Original article
Pages
1-7
Published online
2018-12-20
Page views
2157
Article views/downloads
1475
DOI
Bibliographic record
Medical Research Journal 2019;4(1):1-7.
Keywords
Breast cancer
MDA
TAC
GSH
GSSG
Glutathione redox status
Authors
Taha I. Hewala
Moustafa R. Abo Elsoud
References (23)- Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014; 24(10): R453–R462.
- Tas F, Hansel H, Belce A, et al. Oxidative stress in breast cancer. Med Oncol. 2005; 22(1): 11–15.
- Sharhar S, Normah H, Fatimah A, et al. Antioxidant intake and status, and oxidative stress in relation to breast cancer risk: a case-control study. Asian Pac J Cancer Prev. 2008; 9(2): 343–349.
- Kang DH. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues. 2002; 13(4): 540–549.
- Rajneesh CP, Manimaran A, Sasikala KR, et al. Lipid peroxidation and antioxidant status in patients with breast cancer. Singapore Med J. 2008; 49(8): 640–643.
- Panis C, Victorino VJ, Herrera AC, et al. Can Breast Tumors Affect the Oxidative Status of the Surrounding Environment? A Comparative Analysis among Cancerous Breast, Mammary Adjacent Tissue, and Plasma. Oxid Med Cell Longev. 2015; 2015: 6429812.
- Zitka O, Skalickova S, Gumulec J, et al. Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients. Oncol Lett. 2012; 4(6): 1247–1253.
- Haskell CM, Lowitz BB, Casciato AD. Breast cancer. In: Casciato AD and ; eds. Manual of clinical oncology; 2nd ed. Little and Brown Company, Boston, Toronto (pub. ) 1985, pp. : 150–65.
- Rintoul RF. Operations on the breast. In: Farquhaerisons text book of operative surgery; 7th ed. Churchill living stone 1986: 270–81.
- Abeloff MD, Lichter AS, Niederhuber JE, Pierce LJ, Aziz DC. Breast.Abeloff MD, Armitage JO, Licher AS, Niederhuber JE. ed. Clinical Oncology. Churchil livingstone Inc. 1995: 1617–1714.
- Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem. 1980; 106(1): 207–212.
- Zitka O, Skalickova S, Gumulec J, et al. Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients. Oncol Lett. 2012; 4(6): 1247–1253.
- Kirlin WG, Cai J, Thompson SA, et al. Glutathione redox potential in response to differentiation and enzyme inducers. Free Radic Biol Med. 1999; 27(11-12): 1208–1218.
- Marnett L. Oxyradicals and DNA damage. Carcinogenesis. 2000; 21(3): 361–370.
- Datta K, Sinha S, Chattopadhyay P. Reactive oxygen species in health and disease. Natl Med J India. 2000; 13(6): 304–310.
- Matés JM, Pérez-Gómez C, Núñez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem. 1999; 32(8): 595–603.
- Rajneesh CP, Manimaran A, Sasikala KR, et al. Lipid peroxidation and antioxidant status in patients with breast cancer. Singapore Med J. 2008; 49(8): 640–643.
- Wayner DD, Burton GW, Ingold KU, et al. The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim Biophys Acta. 1987; 924(3): 408–419.
- Wang XL, Rainwater DL, VandeBerg JF, et al. Genetic contributions to plasma total antioxidant activity. Arterioscler Thromb Vasc Biol. 2001; 21(7): 1190–1195.
- Mahmood IH, Abdullah KS, Abdullah MS. Total antioxidant status in women with breast cancer. Pak J Med Sci. 2009; 25: 609–12.
- Yeh CC, Hou MF, Wu SH, et al. A study of glutathione status in the blood and tissues of patients with breast cancer. Cell Biochem Funct. 2006; 24(6): 555–559.
- Navarro J, Obrador E, Carretero J, et al. Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radical Biology and Medicine. 1999; 26(3-4): 410–418.
- Pande D, Negi R, Karki K, et al. Oxidative damage markers as possible discriminatory biomarkers in breast carcinoma. Transl Res. 2012; 160(6): 411–418.